Evidence map›Paper›PMID 35579419›Full record

ArticleBioengineered2022

Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.

Wan-Rong Yi, Mei-Juan Tu, Ai-Xi Yu, Jun Lin, Ai-Ming Yu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. SIRT1 and miR-34a as Potential Plasma Biomarkers in the Acute Phase of Ischemic Stroke.International journal of molecular and cellular medicine · 2025
    Article
  4. Article
  5. Article
  6. Non-coding RNAs regulating mitochondrial function in cardiovascular diseases.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Wan-Rong YiDepartment of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Mei-Juan TuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA.
Ai-Xi YuDepartment of Orthopaedic Trauma and Microsurgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Jun LinDepartment of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Ai-Ming YuDepartment of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA.
University of California, Davis · USWuhan University · CNZhongnan Hospital of Wuhan University · CN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Novel bioengineered microRNA therapeutics for lung cancerR01CA225958 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Aiming Yu · 2019 to 2026
$3.7M
Supplement: Recombinant microRNAs in xenobiotic metabolism and dispositionR35GM140835 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2021 to 2025
$2.0M
Recombinant microRNAs in xenobiotic and nutrient dispositionR01CA253230 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Meijuan Tu · 2021 to 2026
$1.7M
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA225958NCI NIH HHS R01 CA253230NIGMS NIH HHS R35 GM140835
6 · The paper itself

Abstract

Genome-derived microRNAs (miRNAs or miRs) control post-transcriptional gene expression critical for various cellular processes. Recently, we have invented a novel platform technology to achieve high-yield production of fully humanized, bioengineered miRNA agents (hBERAs) for research and development. This study is aimed to produce and utilize a new biologic miR-34a-5p (or miR-34a) molecule, namely, hBERA/miR-34a, to delineate the role of miR-34a-5p in the regulation of mitochondrial functions in human carcinoma cells. Bioengineered hBERA/miR-34a was produced through in vivo fermentation production and purified by anion exchange fast protein liquid chromatography. hEBRA/miR-34a was processed to target miR-34a-5p in human osteosarcoma and lung cancer cells, as determined by selective stem-loop reverse transcription quantitative polymerase chain reaction analysis. The mitochondrial inner membrane protein MPV17 like 2 (

Indexed as

Biological ProductsBone NeoplasmsCarcinomaLung NeoplasmsMembrane ProteinsMicroRNAsMitochondriaMitochondrial ProteinsCell ProliferationHumansBiological ProductsMembrane ProteinsMicroRNAsMIRN34 microRNA, humanMitochondrial ProteinsMPV17L2 protein, humanBioengineeredcancer metabolismmiR-34amiRNAmitochondriaMPV17L2

Identifiers

PMID35579419
PMCPMC9276019
OpenAlexW4280550259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.